Lombard Odier Asset Management Europe Ltd Invests $521,000 in Stryker Corporation $SYK

Lombard Odier Asset Management Europe Ltd bought a new stake in Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,656 shares of the medical technology company’s stock, valued at approximately $521,000.

A number of other hedge funds have also bought and sold shares of SYK. Norges Bank purchased a new position in Stryker in the fourth quarter worth $1,822,272,000. Bank of America Corp DE purchased a new stake in shares of Stryker during the 2nd quarter valued at $1,404,284,000. Auto Owners Insurance Co raised its stake in shares of Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after purchasing an additional 2,906,448 shares during the period. Legal & General Group Plc bought a new stake in shares of Stryker during the 2nd quarter worth $707,212,000. Finally, Jupiter Topco LLC purchased a new position in shares of Stryker in the 2nd quarter worth about $681,581,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Up 2.9%

NYSE:SYK opened at $331.32 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The stock’s fifty day moving average price is $329.10 and its two-hundred day moving average price is $331.47. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market cap of $127.08 billion, a P/E ratio of 34.33, a P/E/G ratio of 2.05 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the previous year, the business earned $3.13 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 351,267 shares of company stock valued at $118,197,701 in the last quarter. 4.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

SYK has been the subject of several research reports. Argus set a $370.00 price target on shares of Stryker in a research report on Thursday, July 9th. Needham & Company LLC lowered their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. BTIG Research dropped their target price on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $361.00 price target on shares of Stryker in a research note on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.